24-hour Lung Function in Subjects With Moderate to Very Severe COPD After Treatment With PT003, Open-Label Spiriva® Respimat® as an Active Control, and Placebo

PHASE3CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 1, 2015

Primary Completion Date

August 1, 2015

Study Completion Date

March 1, 2016

Conditions

COPD

Interventions

DRUG

GFF MDI (PT003)

DRUG

Placebo MDI

DRUG

Spiriva® Respimat® (Tiotropium Bromide)

Tiotropium Bromide Inhalation Solution; Spiriva® Respimat® (Spiriva)